Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, announced a multi-year strategic research collaboration with Merck, known as MSD outside of the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.